ArticleJournal of lipid research2016
ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.
Article in Journal of lipid research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Dietary ω3 Fatty Acids and Phytosterols in the Modulation of the HDL Lipidome: A Longitudinal Crossover Clinical Study.Nutrients · 2023Trial
- Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment.Molecules (Basel, Switzerland) · 2020Trial
- Phytosterols and Omega 3 Supplementation Exert Novel Regulatory Effects on Metabolic and Inflammatory Pathways: A Proteomic Study.Nutrients · 2017Trial
- Lipoprotein-Specific Fatty Acid Profiles in Familial Hypercholesterolemia: Associations with Cardiovascular History and Dietary Patterns.Nutrients · 2025Article
- ApoJ and apoL1 as novel determinants of MASH: a cross-sectional study.Lipids in health and disease · 2025Article
- Alterations of lipoprotein subfractions in GH-deficient adults.Frontiers in endocrinology · 2025Article
- APOL1 polymorphisms are not influencing acute coronary syndrome risk in Czech males.Molecular genetics & genomic medicine · 2024Article
- The association between metabolic syndrome and insulin resistance with risk of cardiovascular events in different states of cardiovascular health status.Journal of diabetes investigation · 2024Article
- Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology.International journal of molecular sciences · 2022Article
- Vitamin D Binding Protein and Renal Injury in Acute Decompensated Heart Failure.Frontiers in cardiovascular medicine · 2022Article
- Familial Hypercholesterolemia: Do HDL Play a Role?Biomedicines · 2021Review
- Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia.Current atherosclerosis reports · 2021Review
- Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism.Scientific reports · 2019Article
- APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.PloS one · 2019Article
- Article
- Pharmacological Intervention to Modulate HDL: What Do We Target?Frontiers in pharmacology · 2017Review
- High density lipoproteins and kidney function: the friend turned foe?Journal of thoracic disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HDL composition rather than HDL-cholesterol (HDL-C) levels seems to be a key determinant of HDL-induced atheroprotection. Heterozygous familial hypercholesterolemia (FH) patients, with lifelong exposure to high LDL levels, show a high prevalence of premature coronary artery disease. We hypothesized that HDL of FH patients might have a modified protein composition and investigated the proteomic signature of HDL obtained from FH patients and their unaffected relatives. HDLs were characterized by 2D electrophoresis/MS in 10 families from the SAFEHEART cohort (3 individuals/family: 2 with genetic FH diagnosis and 1 non-FH relative) clinically characterized and treated as per guidelines. FH patients had lower apoA-I levels and a differential HDL distribution profile of apoL1 and apoA-IV. ELISA validation revealed decreased apoL1 serum levels in FH patients. ApoL1 levels were able to predict presentation of an ischemic cardiac event, and apoL1/HDL-C ratio was associated with the survival rate after the event. FH patients who died because of a fatal cardiac event had lower apoL1 and LCAT content in HDL3 an average of 3.5 years before the event than those who survived. Changes in HDL protein composition could affect patients' prognosis. The proteomic profile of apoL1 is modified in HDLs of high cardiovascular risk patients, and apoL1 plasma levels are significantly lower in serum and in HDL3 of patients that will suffer an adverse cardiac event within 3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.